子痫前期与Foxp3表达量及其基因位点924（rs2232365）多态性的相关性

目的探讨子痫前期患者胎盘Foxp3 的表达变化和Foxp3-924（rs2232365）基因位点多态性与子痫前期的相关性。方法
选取2010年10月~2011年12月在广州医医科大学附属第三医院产科住院的子痫前期患者156例，和同期住院分娩的正常妊娠
孕妇252例，应用PCR-SSP技术进行Foxp3-924（rs2232365）基因位点分型。在上述对象中随机选择子痫前期患者68例，其中轻
度痫前期患者33 例，重度痫前期患者35 例，正常晚期妊娠患者30 例，采用免疫组织化学法检测蜕膜Foxp3 的表达。结果
Foxp3在轻度子痫前期和重度子痫前期组的表达阳性率分别为51.52%和28.57%，显著低于正常妊娠组（86.67%，P<0.05）；子痫
前期的Foxp3-924G/G、G/A、A/A 表型频率分别为：0.1346、0.4615、0.4038，对照组分别为0.1508、0.4087、0.4405；子痫前期组
Foxp3-924 A、Foxp3-924 G 基因频率分别为：0.6346和0.3654，对照组分别为：0.6448和0.3552；Foxp3-924各种基因型频率在子
痫前期组与正常对照组之间差异无统计学意义（P>0.05）。结论子痫前期患者胎盘组织中的Foxp3 表达量显著性低于正常孕
妇，提示Foxp3表达量的水平下降使其免疫抑制功能减弱，母胎免疫耐受失衡，诱导子痫前期的发生；Foxp3-924（rs2232365）位
点基因多态性对子痫前期发生无显著性作用与影响。

Placental Foxp3 expression in patients with preeclampsia and correlation of Foxp3 gene lo-cus 924 (rs2232365) polymorphism with preeclampsia

Objective To detect changes of Foxp3 expression in the decidua in patients with preeclampsia and investigate the
correlation of Foxp3-924 (rs2232365) polymorphisms with preeclampsia. Methods From October 2011 to December 2012, 252
normal pregnant women and 156 preeclampsia patients of Han nationality from the same geographic region were tested for
Foxp3-924 genotypes by polymerase chain reaction with sequence-specific primer (PCR-SSP). Sixty-eight of the patients with
preeclampsia (33 with mild and 35 with severe preeclampsia) and 30 of the normal pregnant women were also examined for
Foxp3 expression in the decidua using immunohistochemical method. Results Foxp3 positive expression rates in the decidua
was 51.52% in mild preeclampsia and 28.57% in severe preeclampsia cases, significantly lower than that in the control group
(86.67%, P<0.05). In preeclampsia patients, the frequencies of Foxp3-924G/G, G/A, and A/A genotypes were 0.1346, 0.4615 and
0.4038, respectively, and the frequencies of Foxp3-924A and Foxp3-924 G were 0.6346 and 0.3654, respectively. The genotype
frequencies of Foxp3-924G/G, G/A and A/A in the control group were 0.1508, 0.4087 and 0.4405, respectively, and the
frequencies of Foxp3-924 A and Foxp3-924 G were 0.6448 and 0.3552, respectively. No significant differences were found in the
gene frequencies of Foxp3-924G/A between preeclampsia patients and the control group (P>0.05). Conclusion The expression
level of Foxp3 in the placental tissue of preeclampsia patients is significantly lower than that in normal pregnant women,
suggesting that lowered Foxp3 expression decreases the immunosuppressive function and causes imbalance of immune
tolerance between maternal-fetal to induce preeclampsia. Foxp3-924 polymorphisms is not significantly correlated with the
occurrence of preeclampsia.